Baseline clinical characteristics of patients with favorable and poor outcome groups
| Variables | ALL (n=215) | 90d-mRS≤2 (n=118) | 90d-mRS>2 (n=97) | P-value |
| Demographic characteristics | ||||
| Age, y, median (IQR) | 70(62, 76) | 67(58, 75) | 73(66, 77) | <0.001 |
| Male, n (%) | 125 (58.1) | 76 (64.4) | 49 (50.5) | 0.052 |
| Past Medical History, n (%) | ||||
| Hypertension | 127 (59.1) | 63 (53.4) | 64 (66.0) | 0.071 |
| Diabetes mellitus | 22 (10.2) | 10 (8.5) | 12 (12.4) | 0.374 |
| Atrial fibrillation | 124 (57.7) | 54 (45.8) | 70 (72.7) | <0.001 |
| Clinical data | ||||
| Admission SBP, median (IQR) | 152(137, 169) | 152(137, 168) | 152(140, 170) | 0.378 |
| Admission DBP, median (IQR) | 84(75, 93) | 84(76, 93) | 83(75, 92) | 0.552 |
| Admission NIHSS, median, (IQR) | 13(11, 18) | 12(10, 16) | 16(12, 19) | <0.001 |
| Admission ASPECT, median, (IQR) | 9 (7, 10) | 9 (8, 10) | 7 (5, 9) | <0.001 |
| IV-rtPA, n (%) | 32 (14.9) | 18 (15.3) | 14 (14.4) | 1 |
| Occlusion site, n (%) | 0.094 | |||
| ICA | 91 (42.3) | 42 (35.6) | 49 (50.5) | |
| MCA-M1 | 107 (49.8) | 66 (55.9) | 41 (42.3) | |
| MCA-M2 | 17 (7.9) | 10 (8.5) | 7 (7.2) | |
| TOAST type, n (%) | 0.002 | |||
| LAA | 57 (26.5) | 38 (32.2) | 19 (19.6) | |
| CE | 133 (61.9) | 61 (51.7) | 72 (74.2) | |
| Others | 25 (11.6) | 19 (16.1) | 6 (6.2) | |
| Procedure process | ||||
| OTP, median (IQR) | 300(220, 390) | 290(210, 360) | 312(225, 420) | 0.097 |
| OTR,median (IQR) | 358(270, 450) | 345(270, 421) | 364(274, 506) | 0.166 |
| Collateral, n (%) | <0.001 | |||
| poor | 67 (31.2) | 21 (17.8) | 46 (47.4) | |
| good | 148 (68.8) | 97 (82.2) | 51 (52.6) | |
| First Attempt Approach, n (%) | 0.078 | |||
| Stent retriever | 59 (27.4) | 39 (33.1) | 20 (20.6) | |
| Direct aspiration | 102 (47.4) | 47 (39.8) | 55 (56.7) | |
| Stent retriever+aspiration | 13 (6.0) | 7 (5.9) | 6 (6.2) | |
| Balloon/stenting angioplasty | 41 (19.1) | 25 (21.2) | 16 (16.5) | |
| eTICI | 0.005 | |||
| 2b50 (50–66%) | 28 (13.0) | 9 (7.6) | 19 (19.6) | |
| 2b67 (67–89%) | 27 (12.6) | 10 (8.5) | 17 (17.5) | |
| 2c | 33 (15.3) | 19 (16.1) | 14 (14.4) | |
| 3 | 127 (59.1) | 80 (67.8) | 47 (48.5) | |
| TTPC5,sec, median (IQR) | 2.6 (2.3, 2.9) | 2.6 (2.4, 2.9) | 2, 6 (2.1, 2.9) | 0.037 |
| TTPM4,sec, median (IQR) | 4.2 (3.7, 4.8) | 4.3 (3.9, 4.8) | 4.1 (3.6, 4.7) | 0.16 |
| TTPVR,sec, median (IQR) | 7.9 (7.2, 8.9) | 7.8 (7.0, 8.4) | 8.2 (7.6, 9.4) | 0.001 |
| CCTC5-M4,sec, median (IQR) | 1.6 (1.0, 2.3) | 1.6 (1.1, 2.4) | 1.6 (1.0, 2.3) | 0.679 |
| CCTC5-VR,sec, median (IQR) | 5.2 (4.4, 6.3) | 5.0 (4.2, 5.8) | 5.8 (4.7, 6.8) | <0.001 |
| CCTM4-VR,sec, median (IQR) | 3.6 (3.0, 4.4) | 3.3 (2.9, 3.9) | 4.2 (3.3, 4.9) | <0.001 |
ASPECT, Alberta Stroke Program Early CT; CCTC5-M4, cerebral circulation time from the vertical intracavernous portion of the internal carotid artery to the cortical segment of the rolandic artery; CCTC5-VR, cerebral circulation time from the vertical intracavernous portion of the internal carotid artery to the rolandic vein; CCTM4-VR, cerebral circulation time from the cortical segment of the rolandic artery to the rolandic vein; CE, cardioembolic; DBP, diastolic blood pressure; eTICI, expanded Thrombolysis in Cerebral Infarction; ICA, internal carotid artery; IQR, interquartile range; IV-rtPA, intravenous alteplase; LAA, large-artery atherosclerosis; MCA-M1, M1 segment of the middle cerebral artery; MCA-M2, M2 segment of the middle cerebral artery; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OTP, onset-to-puncture time; OTR, onset-to-reperfusion time; SBP, systolic blood pressure; SD, standard deviation; TOAST, the Trial of ORG 10172 in Acute Stroke Treatment; TTPC5, time to peak of the vertical intracavernous portion of the internal carotid artery; TTPM4, time to peak of the cortical segment of the rolandic artery; TTPVR, time to peak of the rolandic vein.